Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 163 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy MOST POPULAR Foodie Friday: Butternut Squash Macaroni Casserole September 24, 2021 Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community November 13, 2021 Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 Breast cancer mortality down 66% in 20 years June 13, 2023 Load more HOT NEWS Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... Shannen Doherty Opens Up About Life After Cancer And BH90210 Aspartame and cancer – sweet nothings? John Travolta Supports Olivia Newton-John As She Battles Cancer
